Respira Labs

Today, Chronic Obstructive Pulmonary Disease (COPD) affects 25 million Americans and costs the healthcare system nearly $50 billion a year. Respira Labs’ COPD management platform is based on a novel technology which instead of merely listening for changes in breathing like other wearable tools, emits sound from small sensors to capture personalized lung volume profiles based on resonance. This allows the technology to detect air trappings (abnormal increase in volume of residual air in the lungs after exhalation) which signals an exacerbation. Intelligent algorithms will flag patients in danger of readmission before acute symptoms arise, enable home-based intervention, cut hospital readmission costs, and reduce provider and payer healthcare bills. Initial customers will include heads of telemedicine who run hospital remote patient monitoring systems and who will champion adoption of the Respira Labs solution. Platform users are primary care physicians, pulmonologists, nurse practitioners, respiratory therapists, and post-hospital discharge COPD patients.